Espressione di oncogeni di proliferazione e morte cellulare nel carcinoma superficiale della vescica: Expression of oncogenes in relation to cell proliferation and death in superficial bladder carcinoma

1995 ◽  
Vol 62 (2) ◽  
pp. 216-228
Author(s):  
G. Ferrari ◽  
G. Castagnetti ◽  
A. Dotti ◽  
G. Galizia ◽  
P. Ferrari ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Neoplastic Progression ◽  
P53 Expression ◽  
Proliferation Indices ◽  
Superficial Bladder Carcinoma ◽  
Progression Of Disease ◽  
The One ◽  
Definition Of

Although superficial bladder cancer may be considered “benign”, it is still today a many-sided neoplasm with a prognosis that cannot be well-defined with known traditional parameters. Proliferation indices Ki67 and AgNOR associated with the expression of some oncogenes (p53, Rb, c-myc, BCL2, c-erbB-2) in relation to traditional parameters could help in the prognosis definition of individual patients. 111 patients with superficial bladder cancer were studied for this purpose, relating the grade, stage, follow-up and morphotype to the proliferation indices. Significant correlations were found with AgNOR, but only for grade with Ki67. The study of the oncoproteins and their different expression showed that those alterations typical of infiltration are already present in the superficial forms, with a significant correlation between oncogenic alterations and grade and stage of disease (p53, Rb) on the one hand, and above all of disease-free interval and progression (c-erbB-2) on the other. Lastly, assessment of the oncoproteins c-myc and BCL2, oncogenes connected with the programmed cell death mechanism (apoptosis), showed important correlations with the neoplastic progression of disease in relation to the p53 expression and proliferative activity.

Immunophenotype of Inflammatory Cells in the Bladder Mucosa of Patients Treated with Intravesical BGG for Superficial Bladder Carcinoma

1993 ◽  
Vol 60 (4) ◽  
pp. 325-328
Author(s):  
F. Montefiore ◽  
P.G. Betta ◽  
G. Leva ◽  
D. Tiranti ◽  
S. Treffiletti ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prophylactic Treatment ◽  
Superficial Bladder Cancer ◽  
Inflammatory Cells ◽  
Bladder Mucosa ◽  
Local Inflammatory Response ◽  
Immunohistochemical Technique ◽  
Superficial Bladder Carcinoma

The evolution of the local inflammatory response after conclusion of BCG endovesical prophylactic treatment of superficial bladder cancer recurrences was evaluated in 12 patients. Microscopic specimens obtained during follow-up cystoscopy were examined using an immunohistochemical technique. After suspension of BCG treatment (as well as during treatment) the phlogistic pattern is mainly represented by T-lymphocytes and particularly by the helper/inducer phenotype. No difference in the lymphocyte phenotype was observed between patients who responded and did not respond to BCG. In more than 50% of responders (but never in non-responders) aggregations of immunocompetent cells were observed, the role of which, although needing a larger series of observations, may be of some importance in preventing cancer recurrences.

832: Optimized Intravesical Mitomycin C Treatment for Superficial Bladder Cancer: Long-Term Follow-Up

2006 ◽  
Vol 175 (4S) ◽  
pp. 268-269 ◽  
Author(s):  
Jessie L. Au ◽  
Robert A. Badalament ◽  
M. Guillaume Wientjes ◽  
Donn C. Young ◽  
Tong Shen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Long Term Follow Up

596 UROVYSION© VS TRADITIONAL SURVEILLANCE FOR FOLLOW–UP OF PATIENTS WITH SUPERFICIAL BLADDER CANCER

2007 ◽  
Vol 6 (2) ◽  
pp. 171 ◽  
Author(s):  
S. Gudjonsson ◽  
B.L. Isfoss ◽  
K. Hansson ◽  
A.M. Domanski ◽  
J. Warenholt ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Traditional Surveillance

Bladder cancer

2019 ◽  
Vol 13 (6) ◽  
pp. 271-277
Author(s):  
Ian Peate
Keyword(s):  
Bladder Cancer ◽  
Treatment Options ◽  
Older Person ◽  
Multiple Choice Questions ◽  
Men And Women ◽  
Treatment Regimens ◽  
Common Cancer ◽  
The One ◽  
The Uk

This article is the one in the cancer series that discusses bladder cancer. Bladder cancer can occur in men and women; however, in the UK, there are more men with bladder cancer than women. It is also a disease of the older person. This article provides an introduction that discusses the condition. An overview of the anatomy of the bladder and ureters is provided. In 2015, bladder cancer was the 10th most common cancer in the UK and was responsible for 3% of all new cancer cases. Diagnosis and treatment options are discussed, with an emphasis on ensuring that the patient is key in any decisions that are made about treatment regimens. The importance of follow-up after treatment is also discussed. A glossary of terms is provided and five multiple-choice questions are included to enhance learning and application to practice.

scholarly journals The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up

2014 ◽  
Vol 39 (3) ◽  
pp. 137-142 ◽  
Author(s):  
Caner Dogan ◽  
Eyyüp Sabri Pelit ◽  
Asif Yildirim ◽  
Itir Ebru Zemheri ◽  
Cengiz Canakci ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Diagnosis ◽  
Superficial Bladder Cancer

Results after two years of follow up after intravesical thermochemotherapy with heated mitomycin 40 in patients with high-risk superficial bladder cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 512-512
Author(s):  
Thomas Alexander Voegeli ◽  
Eric Frank ◽  
Christian Bach ◽  
Catejan Nzeh
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Alternative Treatment ◽  
Superficial Bladder Cancer ◽  
Treatment Options ◽  
High Rate ◽  
Intravesical Therapy ◽  
Bladder Irrigation ◽  
Metastatic Prostate Carcinoma

512 Background: Standard management of high risk TCC is either BCG or radical cystectomy, alternative treatment options are limited. It is known that the anti-tumor effect of heated mitomycin is 10 fold higher than at room temperature, which is the standard of intravesical therapy. We herein report the first 2 year follow up (FU) after intravesical therapy with heated mitomycin in a cohort of patients with high risk superficial bladder cancer (TCC). Methods: Treatment was performed for 1 hour with machine bladder irrigation (COMBAT) which maintaines temperature of mitomycin (40 mg) exactly at 43 C. Patients underwent therapy with a 6 week course of weekly treatment and were than followed by cystoscopy every 3 month and if necessary biopsy. Results: We identified 62 patients out of a total group of 108 patients who met the inclusion criteria for high risk TCC according to the EAU Guidelines and who got the complete 6 courses of treatment. 2 were lost of follow up, 1 died due to cardiac problems and 1 from metastatic prostate carcinoma. The remaining 58 patients had a mean FU of 26 month (16-54 m) and included 20 non-responders to BCG. 48/58 patients had CIS or pT1 Tumors or both, 10 patients had pTa+CIS. There were 5 recurrences, all superficial stage pTa, one in the rigth ureter, all could be managed without cystectomy. 8 patients had progressive or recurrent CIS/pT1 or were progressive to pT2 after therapy and underwent cystectomy. Conclusions: In this high risk cohort of 58 patients with a high rate of BCG non-responders only 8 patients had to undergo cystectomy during a 2 year follow up. Intravesical therapy with heated mitomycin is safe and well tolerated and may be an additional alternative treatment before cystectomy is performed in high risk patients with high risk TCC or BCG non responders.

Sign in / Sign up

Export Citation Format

Share Document